We are currently restructuring our databases, so be advised that the FCPAC database is updated only through July 30, 2025.

Processing your request


please wait...

 | Investigations Dataset

Stanford Foreign Corrupt Practices Act Clearinghouse a Collaboration with Sullivan & Cromwell LLP

Investigations Dataset

 
Investigation into Talecris' Activities in Multiple Countries · Talecris Biotherapeutics Holdings Corp./Grifols, S.A.

Information & Summary

Investigation into Talecris' Activities in Multiple Countries

Related FCPA Matter:   Talecris Biotherapeutics Holdings Corp.'s Involvement in Eastern Europe and Middle East Information

Information & Summary

Investigation Name:    Investigation into Talecris' Activities in Multiple Countries

Trend:    None

Type of investigation:    Internal, DOJ

Other Agencies Investigating/Assisting with DOJ Investigation:    Unknown

Whistleblower:    Unknown

Summary

Talecris Biotherapeutics Holdings Corp (Talecris) was a biopharmaceutical company that was one of the largest producers and marketers of plasma-derived protein therapies in the world. It had facilities in North Carolina.

During the course of an unrelated review sometime prior to July 2009, Talecris discovered possible FCPA misconduct in certain Eastern European and Middle Eastern countries, and the company instituted an internal investigation into the possible misconduct. Talecris then voluntarily disclosed the investigation to the DOJ in July 2009. As the internal investigation proceeded, it expanded to a number of other countries. The internal investigation found some FCPA misconduct.

In 2011, Talecris was acquired by Grifols S.A. and shortly thereafter, Grifols presented the findings of Talecris' internal investigation to the DOJ.

In November 2012, the DOJ notified Grifols that it had concluded its investigation and declined to bring any charges against the company. The DOJ cited Grifols cooperation, compliance programs, and remedial measures as part of its decision. Despite the declination, Grifols continued to review possible misconduct. That continued investigation eventually expanded to include Mexico and the Czech Republic, but no FCPA misconduct was found in those countries.

Protected Content


Please Log In or Sign Up for a free account to access restricted features of the Clearinghouse website, including the Advanced Search form and the full case pages.

When you sign up, you will have the option to save your search queries performed on the Advanced Search form.